Ligand Pharmaceuticals Inc (OQ:LGND)

Apr 08, 2024 08:15 am ET
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible.
Apr 03, 2024 09:00 am ET
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
Mar 05, 2024 04:01 pm ET
Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m. Eastern Time.
Mar 04, 2024 08:00 am ET
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee. The grant date for the options was March 1, 2024.
Feb 27, 2024 07:00 am ET
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call and webcast today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.
Feb 22, 2024 04:01 pm ET
Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour and Welfare for the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa® (perampanel) in Japan as an alternative therapy when oral administration is temporarily not possible. Fycompa is formulated with Captisol®, a Ligand technology.
Feb 16, 2024 08:00 am ET
Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice President of Clinical Strategy and Investments. Both executives will report to CEO Todd Davis.
Feb 13, 2024 04:01 pm ET
Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to discuss financial results and provide a general business update.
Feb 01, 2024 05:00 pm ET
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective February 1, 2024, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 93,700 shares of its common stock, 32,750 restricted stock units (“RSUs”) and 40,000 performance stock units (“PSUs”) (at the target level) to two non-executive employees. The grant date for the options, the RSUs and the PSUs was February 1, 2024.
Jan 10, 2024 07:30 pm ET
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, and Shanghai Henlius Biotech, Inc. (2696.HK), today announced a...
Jan 05, 2024 04:30 pm ET
U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections.
Dec 12, 2023 12:01 pm ET
Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand’s senior management team provided an overview of the company’s business model and investment selection process, reviewed the progress of the portfolio including near-term partner milestones, and introduced 2024 guidance. A copy of the presentation and a replay of the webcast are available at
Dec 12, 2023 09:00 am ET
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC) harboring ESR1 mutations, today broadly shared the three poster presentations...
Dec 06, 2023 04:02 pm ET
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023.
Dec 01, 2023 08:20 am ET
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet N
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, and Ligand...
Nov 28, 2023 09:01 am ET
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that it had five abstracts accepted as poster...
Nov 08, 2023 04:01 pm ET
Ligand Reports Third Quarter 2023 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions.
Nov 06, 2023 09:00 am ET
Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that a case report detailing a durable complete...
Nov 01, 2023 08:00 am ET
Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has acquired Tolerance Therapeutics, Inc. (“Tolerance Therapeutics”) for $20 million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of TZIELD (teplizumab-mzwv), that is owed a royalty of less than 1% on worldwide net sales. The transaction will be immediately accretive to Ligand’s royalty revenue.
Oct 25, 2023 04:01 pm ET
Ligand To Report Third Quarter 2023 Financial Results On November 8
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
Oct 18, 2023 08:00 am ET
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today...
Oct 02, 2023 09:00 am ET
Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today shared the results of EQUALS 2 (ESR1 QUAlity of Life Survey...
Sep 27, 2023 09:00 am ET
Ligand Acquires Assets of Novan, Inc. for $12.2 Million
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has closed the transaction to acquire assets of Novan, Inc. (“Novan”) following the offer it made on July 17, 2023. On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to provide up to $15 million in debtor-in-possession (“DIP”) financing. In September 2023, the Bankruptcy Court approved a $12.2 million bid from Ligand to purchase berdazimer gel and all the assets related to the NITRICIL™ technology platform, and the rights to the Bayer-partnered Sitavig program. The remaining
Sep 26, 2023 05:05 pm ET
Ligand Appoints Martine Zimmermann to its Board of Directors
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand’s board.
Sep 22, 2023 09:00 am ET
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Ly
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been granted marketing authorization by the European Commission (EC) for Enrylaze® (JZP458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (one month and older) who have developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Enryl
Sep 21, 2023 09:20 am ET
Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) (“Travere”) today released topline, two-year confirmatory secondary endpoint results from its pivotal, head-to-head Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) versus irbesartan. FILSPARI demonstrated long-term kidney function preservation and achieved a clinically meaningful difference in estimated glomerular filtration rate (eGFR) total and chronic slope versus irbesartan, narrowly missing statistical significance in eG
Sep 18, 2023 05:17 pm ET
Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand,” the “Company” or “we”) announced that it has entered into a merger agreement, pursuant to which its subsidiary, Pelican Technology Holdings, Inc., (“Pelican”) has become a wholly owned subsidiary of Primrose Bio, Inc. (“Primrose Bio”, formerly known as Primordial Genetics, Inc.). Primrose Bio is a stand-alone private company focused on synthetic biology. As part of the transaction, Ligand retains the existing commercial royalties related to the Pelican Expression Technology® and will own 49.9% of Primrose Bio. Simu
Sep 01, 2023 10:02 pm ET
Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on September 1, 2023, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 5
Aug 08, 2023 04:01 pm ET
Ligand Reports Second Quarter 2023 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Jul 27, 2023 01:30 pm ET
Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Tr
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its collaborator Merck, known as MSD outside of the United States and Canada, today announced positive topline results from two Phase 3 trials evaluating V116, an investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and previously vaccinated individuals. If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults. Results from the STRIDE-3 trial demonstrated statistically significant immune responses compared to PCV20 (pneumococcal 20-valent conjugate vaccine)
Jul 25, 2023 04:30 pm ET
Ligand To Report Second Quarter 2023 Financial Results On August 8
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2023 financial results after the close of the U.S. financial markets on Tuesday, August 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand’s CEO Todd Davis, President and COO Matt Korenberg, and CFO Tavo Espinoza.
Jul 17, 2023 08:59 am ET
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has made an offer to acquire the assets of Novan, Inc. (Nasdaq: NOVN) (“Novan”) for $15 million in cash and provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. Novan announced earlier today that it has filed for Chapter 11 reorganization and its entry into a stalking horse acquisition offer with Ligand. The transaction is designed to preserve and maximize the value of Novan’s commercial business and berdazimer gel development assets. Berdazimer gel is in development
Jul 17, 2023 08:45 am ET
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
Novan, Inc. (Nasdaq: NOVN) and its wholly owned subsidiary, EPI Health, LLC (collectively, “the Company” or “Novan”), today announced that it has entered into a stalking horse asset purchase agreement (“APA”) with Ligand Pharmaceuticals, Inc....
Jun 29, 2023 09:00 am ET
Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it will present two posters, addressing sexual...
Jun 05, 2023 09:01 am ET
Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today broadly shared a poster presentation detailing the results...
May 25, 2023 05:00 pm ET
Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today shared an abstract to be presented at the...
May 16, 2023 07:30 am ET
Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced positive top-line results from its Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The study successfully achieved its primary endpoint, with patients receiving VK2809 experiencing statistically significant reductions in liver fat content from baseline to Week 12 as compared with placebo. The median relative change from bas
May 04, 2023 04:01 pm ET
Ligand Reports First Quarter 2023 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Apr 24, 2023 04:01 pm ET
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update. Speakers on the call will include Ligand’s CEO Todd Davis, President and COO Matt Korenberg, and CFO Tavo Espinoza.
Mar 09, 2023 08:00 am ET
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cance
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, and Guardant Health, Inc. (Nasdaq: GH), a...
Mar 06, 2023 09:00 am ET
Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutat
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast and gynecological cancers harboring ESR1 mutations, today announced that its lead drug candidate,...
Feb 22, 2023 04:01 pm ET
Ligand Reports Fourth Quarter and Full Year 2022 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2022, and provided an operating forecast and business updates. These financial results are presented on a continued operations basis as OmniAb was spun out on November 1, 2022 and is reported as discontinued operations. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Feb 17, 2023 06:30 pm ET
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Travere Therapeutics, Inc. (Nasdaq: TVTX) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
Feb 16, 2023 07:00 am ET
Sermonix Pharmaceuticals and Quantum Leap Healthcare Announce New Study Arm to Evaluate Lasofoxifene in Ongoing I-SPY 2 Clinical Trial
COLUMBUS, Ohio, and SAN FRANCISCO, Feb. 16, 2023 /PRNewswire/ -- Sermonix Pharmaceuticals Inc. and Quantum Leap Healthcare Collaborative™ today announced that Sermonix's investigational next-generation targeted endocrine therapy, lasofoxifene, will be evaluated in a new study arm of the ongoing I-SPY endocrine program sponsored by Quantum Leap. This portion of the study targets patients with newly diagnosed estrogen receptor-positive (ER+) invasive cancer.   
Feb 06, 2023 04:01 pm ET
Ligand to Report Fourth Quarter Financial Results on February 22
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, February 22, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO Todd Davis, President and COO Matt Korenberg and CFO Tavo Espinoza.
Jan 06, 2023 08:05 am ET
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum (molluscum). Assuming the filing is accepted by the FDA and given a typical 12-month review process, Novan anticipates a potential first quarter 2024 approval.
Dec 13, 2022 08:30 am ET
Ligand Provides Highlights from its Investor and Analyst Day Event
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today’s Investor and Analyst Day event its executive management provided an overview of Ligand’s corporate structure and business following the successful spin-off of its OmniAb antibody discovery business, reviewed Ligand’s recent progress and near-term partner milestones and provided an outlook for financial growth. Management also introduced 2023 financial guidance and discussed its capital deployment strategy. A webcast of the event including slides is available
Dec 08, 2022 12:00 pm ET
Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge In
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it will share a poster presentation at...
Dec 05, 2022 07:00 am ET
Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that John Higgins has retired as Chief Executive Officer, effective as of today, and that the company’s board of directors has named Todd C. Davis as Chief Executive Officer. Mr. Higgins will resign as a director of the company on December 31, 2022.
Nov 17, 2022 09:00 am ET
Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it had four abstracts...
Nov 16, 2022 08:00 am ET
Ligand to Hold Investor and Analyst Day on December 13
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time). A live and archived webcast will be available for those unable to attend in person. Presenters will include:
Nov 07, 2022 04:01 pm ET
Ligand Reports Third Quarter 2022 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Nov 01, 2022 04:01 pm ET
Ligand Announces Completion of OmniAb Spin-Off
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the company has completed the expected tax-free spin-off of its OmniAb antibody discovery business which has become OmniAb, Inc., an independent publicly traded company. OmniAb will begin regular-way trading November 2, 2022 on NASDAQ under the stock ticker symbol “OABI.” Ligand continues to trade under the stock ticker symbol “LGND.”
Nov 01, 2022 08:00 am ET
Ligand Distribution of OmniAb Complete and Business Combination Closed
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the completion of its expected tax-free distribution (Distribution) of 100% of Ligand’s interest in its subsidiary OmniAb on a pro rata basis to Ligand shareholders of record as of October 26, 2022. The Distribution was immediately followed by the closing (Closing) of the business combination (Business Combination) between Avista Public Acquisition Corp. II (APAC) (which prior to the Closing domesticated in Delaware and changed its name to OmniAb, Inc., (OmniAb)) and OmniAb, Inc. (which prior to the Closing changed its n
Oct 26, 2022 06:00 pm ET
Ligand to Report Third Quarter Financial Results on November 7
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report third quarter 2022 financial results after the close of the U.S. financial markets on Monday, November 7, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Korenberg and CFO Tavo Espinoza.
Oct 26, 2022 08:00 am ET
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI™ (teclistamab) for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 discovered and developed by Janssen scientists using OmniAb’s OmniRat® antibody discovery technology.
Oct 24, 2022 05:00 pm ET
OmniAb Business Combination Approved by APAC Shareholders
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the business combination (Business Combination) of Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA) and OmniAb, Inc. (OmniAb), was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination. Based on actual redemptions and estimated expenses, OmniAb expects to have approximately $95 million of net cash upon the closing of the Business Combination (Closing). Prior to the Business Combination, APAC will domesticat
Oct 21, 2022 10:00 am ET
Sermonix Pharmaceuticals Shares Additional Findings From Its ELAINE 1 Clinical Study at the 4th Annual Congress of the International Society of Liquid Biopsy
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today shared additional findings from its Evaluation of...
Oct 03, 2022 04:30 pm ET
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on October 3, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 10,770 shares of its common stock to two non-executive employees in connection with their commencement of employment under the Ligand Pharmaceuticals Incorporated 2022 Employee Inducement Plan (the “Inducement Plan”). The stock options were granted as an inducement material to the employees’ commencement of employment and were granted as an employme
Oct 03, 2022 09:00 am ET
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separation of Ligand and OmniAb into two independent, publicly traded companies. The dividend in OmniAb shares is expected to be distributed to Ligand shareholders on or about November 1, 2022, the expected closing date of the previously announced business combination (Business Combination) between OmniAb and Avista
Sep 14, 2022 11:22 am ET
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatm
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, broadly shared a case report detailing the first-ever known...
Sep 13, 2022 09:00 am ET
Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced results of its signal-seeking Evaluation of...
Aug 24, 2022 05:00 pm ET
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI® (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 that was discovered by Janssen scientists using OmniAb’s OmniRat antibody discovery technology.
Aug 08, 2022 04:01 pm ET
Ligand Reports Second Quarter 2022 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Aug 01, 2022 07:22 pm ET
Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective August 1, 2022, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 90,073 shares of its common stock, 5,000 restricted stock units (“RSUs”) and 4,000 performance stock units (“PSUs”) (at the target level) to six non-executive employees. The options were granted on August 1, 2022, and the grant date for the RSUs and the PSUs will be the date on which Ligand files a Form S-8 Registration Statement to register the shares pursuant to Ligand’s 2022 Em
Jul 22, 2022 04:08 pm ET
Ligand to Report Second Quarter Financial Results on August 8
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg.
Jun 29, 2022 04:01 pm ET
Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jason Haas to the Company's Board of Directors. Mr. Haas brings more than 30 years of healthcare investment banking and corporate finance experience to Ligand.
Jun 09, 2022 09:38 am ET
Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it will host a virtual update on its...
May 04, 2022 04:01 pm ET
Ligand Reports First Quarter 2022 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Apr 28, 2022 12:47 pm ET
Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts accepted for presentation at...
Apr 19, 2022 04:01 pm ET
Ligand to Report First Quarter Financial Results on May 4
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, May 4, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.
Apr 08, 2022 04:50 pm ET
Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on April 8, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 40,000 shares of its common stock to Kurt Gustafson, who joined OmniAb, Inc. (OmniAb), Ligand’s antibody discovery business, as its CFO, in connection with his commencement of employment. The stock options were granted as inducement material to Mr. Gustafson’s commencement of employment with Ligand and OmniAb and was granted as an employment inducemen
Mar 23, 2022 04:17 pm ET
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
Ligand Pharmaceuticals Incorporated (Ligand) (NASDAQ: LGND) today announced the signing of a definitive merger agreement with Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA), a publicly traded special purpose acquisition company (SPAC), providing for the spin-off of OmniAb, Inc. (OmniAb), Ligand’s antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC. The combined company will be led by Ligand’s President, Matt Foehr, and will be renamed “OmniAb, Inc.”
Feb 17, 2022 04:01 pm ET
Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2021, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Feb 09, 2022 09:01 am ET
Ligand to Report Fourth Quarter Financial Results on February 17
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2021 financial results after the close of the U.S. financial markets on Thursday, February 17, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.
Dec 22, 2021 08:00 am ET
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner CStone Pharmaceuticals (HKEX: 2616) has received approval from China’s National Medical Products Administration (NMPA) for sugemalimab (Cejemly®), an OmniAb-derived anti-PD-L1 monoclonal antibody, for the first-line treatment of metastatic (stage IV) non-small cell lung cancer (NSCLC) in combination with chemotherapy.
Dec 21, 2021 04:01 pm ET
Ligand and GSK Expand Global Collaboration and License Agreement
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today the expansion of an existing collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK). The expansion will leverage Icagen’s ion-channel-based discovery technology and unique expertise in small molecule therapeutics targeting transmembrane proteins. This new agreement builds upon the initial December 2020 agreement to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.
Dec 13, 2021 10:00 am ET
Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that the company, in collaboration with Dr....
Nov 09, 2021 04:02 pm ET
Ligand Reports Third Quarter 2021 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2021 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Nov 09, 2021 04:01 pm ET
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, and the other featuring Ligand’s existing collection of core royalties and the technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business. The spin-off is intended to create two companies with dedicated operational focus, business-specific capital allocation, agility to meet partner needs, and compelling focused investment profiles.
Oct 26, 2021 04:01 pm ET
Ligand to Report Third Quarter Financial Results on November 9, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and nine months ended September 30, 2021 after the close of the U.S. financial markets on Tuesday, November 9, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.
Oct 21, 2021 09:00 am ET
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical Co., Ltd. (CRDC) exclusive Asia territorial rights to develop a novel investigational oral COVID-19 antiviral therapeutic compound using Ligand’s BEPro technology. Ligand will receive an upfront payment in respect of the collaboration, and if the program advances, clinical and regulatory milestone payments, and tiered royalties on net sales. CRDC will be responsible for all costs related to the program.
Sep 20, 2021 09:31 am ET
Thinking about trading options or stock in Mirati Therapeutics, Pfizer, Ligand Pharmaceuticals, Alibaba, or Equinix?
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRTX, PFE, LGND, BABA, and EQIX.
Aug 30, 2021 07:00 pm ET
Performance Food Group & Digital Turbine Set to Join S&P MidCap 400; TreeHouse Foods & Ligand Pharmaceuticals to Join S&P SmallCap 600
 NEW YORK, Aug. 30, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:
Aug 30, 2021 04:01 pm ET
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Gloria Biosciences (GloriaBio) has received approval from China’s National Medical Products Administration (NMPA) for zimberelimab (GLS-010), an OmniAb-derived anti-PD-1 monoclonal antibody for the treatment of recurrent or refractory classical Hodgkin’s lymphoma (cHL). GloriaBio has development and commercialization rights in China with respect to zimberelimab through a sublicense agreement with Ligand's licensee Wuxi Biologics Ireland Limited.
Aug 16, 2021 02:53 pm ET
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN). The PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater than threefold reduction of proteinuria from baseline after 36 weeks of treatment, compared to the active control irbesartan (p
Aug 16, 2021 10:00 am ET
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 ELAINE 1 Randomized Clinical Trial Assessing Efficacy of Oral Lasofoxifene Versus Intramuscular Fulvestrant
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it has completed enrollment in its Phase 2...
Jul 29, 2021 04:01 pm ET
Ligand Reports Second Quarter 2021 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2021 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Jul 28, 2021 04:00 pm ET
Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms
PALO ALTO, Calif., July 28, 2021 /PRNewswire/ -- Landing AI™ announced today a software licensing agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to incorporate LandingLens™ into Ligand's OmniAb® and xPloration™ antibody discovery platforms. LandingLens™ is a software platform that provides an end-to-end workflow to build, iterate and operationalize AI-powered visual inspection solutions.
Jul 21, 2021 09:00 am ET
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has launched Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), also known as JZP458. Rylaze, which was approved by the FDA on June 30, 2021, is a recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.
Jul 19, 2021 08:00 am ET
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Merck has received approval from the U.S. Food and Drug Administration (FDA) for VAXNEUVANCETM, also known as V114, for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older. VAXNEUVANCE is a 15-valent pneumococcal vaccine utilizing Ligand’s CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology™ platform.
Jul 16, 2021 09:00 am ET
Ligand to Report Second Quarter Financial Results on July 29, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three and six months ended June 30, 2021 after the close of the U.S. financial markets on Thursday, July 29, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.
Jul 14, 2021 04:01 pm ET
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Jennifer Cochran, Ph.D. to the Company's Board of Directors. Dr. Cochran is the Shriram Chair of the Department of Bioengineering at Stanford University, where she also is a professor of bioengineering and (by courtesy) of chemical engineering and a member of the cancer biology, biophysics and immunology programs.
Jun 28, 2021 10:13 am ET
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that enrollment has been completed for its Phase 2...
May 03, 2021 04:01 pm ET
Ligand Reports First Quarter 2021 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Apr 22, 2021 04:01 pm ET
Ligand to Report First Quarter Financial Results on May 3, 2021
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three months ended March 31, 2021 after the close of the U.S. financial markets on Monday, May 3, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg.
Feb 03, 2021 07:30 am ET
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.
Feb 02, 2021 11:59 am ET
Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that their ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) achieved its pre-specified interim FSGS partial remission of proteinuria endpoint (FPRE) after 36 weeks of treatment. Sparsentan, an investigational product candidate, demonstrated a statistically significant response on FPRE compared to the active control, irbesartan (p=0.0094). Preliminary results from the interim analysis suggest that to date in the study,
Jan 27, 2021 08:31 am ET
Thinking about trading options or stock in Pfizer, Ligand Pharmaceuticals, Capital One Financial, GSX Techedu, or National Beverage?
NEW YORK, Jan. 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PFE, LGND, COF, GSX, and FIZZ.
Jan 20, 2021 08:30 am ET
Ligand’s Fourth Quarter Financial Results to be Reported February 3rd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report fourth quarter 2020 financial results on February 3, 2021. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Jan 13, 2021 08:30 am ET
Ligand Receives Milestone Payment from Merck
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that the company will receive a $1.5 million milestone payment from Merck triggered by the U.S. Food and Drug Administration’s (FDA’s) acceptance for review of a biologics license application (BLA) for V114, an investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease in adults.
Dec 21, 2020 08:30 am ET
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today a collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK) to leverage Icagen’s unique expertise in small molecule therapeutics targeting transmembrane proteins. This collaboration will utilize the Icagen discovery technology to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.
Nov 23, 2020 08:30 am ET
Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery platform. Two large multinational pharmaceutical companies with a license to OmniAb have reached clinical-development milestones with their programs. The progress by these companies resulted in a total of $4.5 million in milestone payments being earned by Ligand.
Nov 06, 2020 02:16 pm ET
Ligand’s Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ for the Treatment of Status Epilepticus in Adult and Pediatric Patients
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration (FDA) for SESQUIENT, a Captisol-enabled™ Fosphenytoin (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and pediatric patients.
Oct 30, 2020 08:00 am ET
Ligand Reports Third Quarter 2020 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three- and nine-months ending September 30, 2020 and provided an operating forecast and program updates. Ligand management will host a conference call with slides today beginning at 8:30 a.m. Eastern time to discuss this announcement and answer questions.
Oct 23, 2020 08:30 am ET
Ligand’s Captisol Technology Plays Key Role in the Manufacture of Gilead’s Veklury, the First FDA-Approved COVID-19 Treatment
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today highlighted the company’s role in the manufacturing of Veklury® (remdesivir), Gilead Sciences’ antiviral drug for the treatment of patients with COVID-19 requiring hospitalization. Veklury is formulated with Ligand’s Captisol® technology. Approved yesterday by the U.S. Food and Drug Administration, Veklury is the first and only approved COVID-19 treatment in the United States. The drug is now widely available in hospitals across the country, following Gilead’s early investments to rapidly expand manufacturing
Oct 20, 2020 02:05 pm ET
Ligand Provides Highlights from Today’s Investor Day Event
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today’s virtual Investor Day event its senior management reviewed recent business progress and provided a financial growth outlook. Management also provided updated 2020 financial guidance and introduced a preliminary financial outlook for 2021 to 2023 including 2021 financial guidance, and discussed its three primary technology platforms.
Oct 19, 2020 04:02 pm ET
Ligand’s Third Quarter Financial Results to be Reported October 30th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report third quarter 2020 financial results on October 30, 2020. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.
Oct 12, 2020 09:00 am ET
Ligand to Divest Vernalis Research Operations
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) for $25 million in cash. Under the terms of the agreement, Ligand will retain economic rights on completed collaboration licenses as well as a share of the economic rights on current research collaboration contracts. In addition, Vernalis will continue to support certain existing Ligand partnerships. The transaction is expected to close in the fourth quarter of 2020, subject to customary closing conditions.
Oct 02, 2020 08:00 am ET
Ligand to Host Virtual Investor Day on October 20th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting during the event will be:
Oct 01, 2020 08:24 am ET
Ligand Completes Acquisition of Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in cash, plus one non-transferable contingent value right (CVR) per share representing the right to receive a contingent payment of $78 million in cash if a certain specified milestone is achieved. The acquired company will cease trading on the NYSE American under the symbol PFNX effective as of October 1, 2020.
Sep 30, 2020 08:00 am ET
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain specified milestone is achieved, expired at midnight (New York City time), at the end of the day on Tuesday, September 29, 2020.
Sep 23, 2020 08:00 am ET
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at the highest levels in the history of the technology and position Captisol for major growth. Significant new clinical and regulatory developments with Evomela and Kyprolis, among other drugs, are reinforcing the role the proprietary technology serves in enabling important medicines. During 2020, Ligand has facilitated the successful installation of equipment to allow production at significantly hig
Sep 10, 2020 08:00 am ET
Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology platform. Ligand acquired xCella Biosciences, Inc. for $7 million in cash plus potential earnouts, and acquired Taurus Biosciences LLC for $5 million in cash plus non-transferable contingent value rights (CVRs). In addition, Ligand will invest $2.5 million in a new company, Minotaur Therapeutics, which will be led by Taurus Biosciences’ founder, in exchange for royalties on products from future programs.
Sep 01, 2020 04:02 pm ET
Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference.
Aug 31, 2020 09:00 am ET
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all outstanding shares of common stock of Pfenex, Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractual contingent value right per share representing the right to receive a contingent payment of $2.00 in cash, if a certain specified milestone is achieved. The tender offer is being made pursuant to an Offer to Purchase, dated August 31,
Aug 25, 2020 04:15 pm ET
Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a study of OmniAb-derived IMVT-1401 in patients with myasthenia gravis (MG). Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
Aug 24, 2020 08:30 am ET
Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myel
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug Administration (FDA) approval for the expansion of the KYPROLIS® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX® (daratumumab) plus dexamethasone (DKd) in once- and twice-weekly dosing regimens for the treatment of patients with relapsed or refractory multiple myeloma (R/R MM) who have received one to three previous lines of therapy.
Aug 11, 2020 01:04 pm ET
PFENEX INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
Rigrodsky & Long, P.A. announces that it is investigating Pfenex Inc. (“Pfenex”) (NYSE American: PFNX) regarding possible breaches of fiduciary duties and other violations of law related to Pfenex’s agreement to be acquired by Ligand...
Aug 10, 2020 05:36 pm ET
Ligand to Acquire Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Pfenex Inc. (NYSE American: PFNX) today announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis. In addition, Ligand will pay $2.00 per share or $78 million as a Contingent Value Right (CVR) in the event a predefined regulatory milestone is achieved by December 31, 2021, for a total transaction value of up to $516 million. The closing of this transaction is subject to customary conditions and is expect
Jul 08, 2020 10:00 am ET
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic breast cancer arena, today announced a collaboration with Eli Lilly and Company to...
May 29, 2020 08:00 am ET
Ligand Announces Icagen’s Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Icagen, a Ligand Company, announced today the expansion of Icagen’s license agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders, by adding a second program to the agreement. The new program incorporates Icagen’s ion channel technology and expertise and is directed at a specific novel ion channel target relevant to neurodegenerative disease. The new program is in addition to ongoing work on another novel CNS target.
May 28, 2020 04:22 pm ET
Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has earned a $3 million milestone payment from Palvella Therapeutics as a result of Palvella raising $45 million in an oversubscribed Series C financing to leading biotechnology crossover and venture investors. The milestone payment will consist of $2 million in cash and $1 million in Palvella Series C Preferred Stock.
May 28, 2020 04:08 pm ET
Palvella Therapeutics Completes $45 Million Series C Financing
Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for serious genetic diseases with no approved treatments, today announced the closing of an...
Apr 06, 2020 07:00 am ET
Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provides a general corporate update, as follows:
Apr 02, 2020 04:02 pm ET
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations. As previously announced, the purchase price was $15 million in cash, and Icagen is entitled to receive additional cash payments based on certain revenue achievements.
Mar 18, 2020 09:31 am ET
Thinking about trading options or stock in Apple, Clorox, Electronic Arts, Ligand Pharmaceuticals, or Teladoc Health?
NEW YORK, March 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CLX, EA, LGND, and TDOC.
Mar 10, 2020 08:00 am ET
Ligand’s Presentation at the Barclays Global Healthcare Conference Now a Webcast Only, New Slides Available on Ligand.com
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that today’s scheduled in-person presentation at the Barclays Global Healthcare Conference in Miami Beach was changed by conference organizers to a webcast only, as the conference has been reconfigured. The webcast will take place as previously scheduled at 2:35 p.m. ET and is available
Mar 02, 2020 08:00 am ET
Ligand Pharmaceuticals Management to Present at Two Investor Conferences in March
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at two upcoming investor conferences.
Feb 27, 2020 08:00 am ET
Ligand Raises 2020 Financial Guidance Due to Higher Captisol Material Sales
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces an update to its financial outlook and raises its 2020 financial guidance. Ligand now expects 2020 total revenues to be approximately $133 million and diluted EPS to be $3.62, up from previous guidance for total revenues of approximately $128 million and diluted EPS of $3.45. This increase is due to higher material sales of Ligand’s Captisol technology as a result of multiple recent orders for Captisol to be used with the investigational compound remdesivir. Material sales for 2020 are now expected to be approximately $40 million, up
Feb 19, 2020 08:00 pm ET
INVESTOR ALERT: BDX LGND LOPE SBT: Kirby McInerney LLP Continues Investigation of Shareholder Claims
The law firm of Kirby McInerney LLP is investigating whether the following publicly-traded companies have violated federal securities laws and/or engaged in other unlawful business practices. Becton, Dickinson and Company (NYSE: BDX) On February...
Feb 03, 2020 08:30 am ET
Ligand's Technologies Support and Enable Potential Coronavirus Treatments
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its proprietary technologies are being utilized by partners to support and enable potential treatments for the 2019 novel coronavirus, 2019-nCoV, that originated in Wuhan, China. Technologies that have shown potential or general applicability in the antiviral or therapeutic antibody areas include Ligand’s Captisol, OmniAb and LTP (Liver-Targeted Prodrug) platforms.
Jan 13, 2020 04:02 pm ET
Ligand Enters into OmniAb® Platform License Agreement with Pandion Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Pandion Therapeutics. Under the agreement, Pandion will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™. OmniAb is licensed to over 40 corporate partners globally, and this deal with Pandion adds to a growing portfolio of OmniAb discovery and clinical development programs. Pandion will pay Ligand an up-front platform access fee, development
Dec 23, 2019 08:30 am ET
Two Ligand Pharmaceuticals Board Members Recognized as 2019 Most Influential Corporate Directors by WomenInc. Magazine
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that two members of its Board of Directors, Nancy Gray and Sarah Boyce, have been named to WomenInc. magazine’s 2019 Most Influential Corporate Directors list.
Dec 02, 2019 08:30 am ET
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Sanofi
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb license agreement with Sanofi. Under the agreement, Sanofi will be able to use Ligand’s full OmniAb antibody discovery platform which includes OmniRat®, OmniFlic®, OmniMouse®, OmniChicken® and OmniClic™ in addition to Ligand’s patented antigen technology. OmniAb is licensed to over 40 corporate partners globally, and this deal with Sanofi adds to a growing portfolio of OmniAb discovery and clinical development programs with global fully-integrated pharmaceutical companies. Sanofi will pay Ligand
Nov 12, 2019 08:30 am ET
Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it ranked in Deloitte’s Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech compan
Nov 08, 2019 08:30 am ET
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN Kidney Week 2019 in Washington, D.C. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. The trial achieved the primary endpoint demonstrating pharmacokinetic bioequivalence between CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE™) after intravenous (IV) administration in he
Nov 07, 2019 08:30 am ET
Ligand to Participate in the Stephens 2019 Nashville Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat is scheduled to take place on Wednesday, November 13, 2019 at 3:30 p.m. Eastern Time. Matt Korenberg, CFO will attend for Ligand.
Nov 05, 2019 04:01 pm ET
Ligand Reports Third Quarter 2019 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2019 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Oct 22, 2019 04:01 pm ET
Ligand to Report Third Quarter 2019 Results on November 5th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Oct 15, 2019 09:00 am ET
Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases. Ms. Boyce's appointment increases the number of Ligand directors to nine.
Sep 23, 2019 10:01 am ET
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the...
Aug 29, 2019 09:00 am ET
Ligand to Participate in the H. C. Wainwright 21st Annual Global Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the H.C. Wainwright 21st Annual Global Investment Conference in New York City. Presentation takes place on Tuesday, September 10, 2019 at 8:45 a.m. Eastern Time. John Higgins, CEO, Matt Foehr, COO, and Matt Korenberg, CFO will attend for Ligand.
Aug 12, 2019 09:00 am ET
Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, announces the official product launch of melphalan hydrochloride for injection (EVOMELA) in China which is the first commercial product launch for CASI. EVOMELA uses Ligand’s Captisol technology in its formulation.
Jul 30, 2019 11:30 am ET
Lemelson Capital Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Calls on US Attorney to Investigate
SHELBURNE, Vt., July 30, 2019 /PRNewswire/ -- Lemelson Capital Management (LCM), a private investment management firm, today announced that it had increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND).  The firm today also called on the US Attorney's office for the Southern District of California to investigate Ligand for alleged criminal violations of federal securities laws amidst what LCM has called SEC failures.
Jul 30, 2019 08:00 am ET
Ligand Reports Second Quarter 2019 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2019, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 9:00 a.m. Eastern time to discuss this announcement and answer questions.
Jul 23, 2019 04:15 pm ET
Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash. Ab Initio was a privately held antigen-discovery company based in South San Francisco, California. Antigen design and preparation are the first steps necessary for the discovery of therapeutic antibodies. Some antibody targets are particularly difficult and require a specialized approach to design, prepare and deliver an antigen to enable the successful discovery of an antibody drug candidate. This transact
Jul 16, 2019 11:19 am ET
Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP
SHELBURNE, Vt., July 16, 2019 /PRNewswire/ -- Lemelson Capital Management, LLC (LCM), a private investment management firm, today announced performance results for its flagship Amvona Fund, LP. (The Fund). For 1H 2019, The Amvona Fund returned 70.27 percent net of all fees and expenses, beating by 51.73 percent the benchmark S&P 500 Total Return Index,[2] which returned 18.54 percent during the same period. 
Jul 15, 2019 09:00 am ET
Ligand to Report Second Quarter 2019 Results on July 30th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2019 financial results on July 30, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.
Jul 10, 2019 09:00 am ET
Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Based on top line data, the trial achieved the primary endpoint demonstrating pharmacokinetic bioequivalence between CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE™) after intravenous (IV) administration in healthy ad
Jul 08, 2019 08:30 am ET
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
SAN DIEGO and ZUG, Switzerland, July 8, 2019 /PRNewswire/ -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and SQ Innovation AG today announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand's Captisol® technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure. SQ Innovation is developing a novel drug-device combination for cost-effective subcutaneous delivery of diuretics that currently require intravenous administration by a certified healthcare prof
Jul 08, 2019 08:30 am ET
Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and SQ Innovation AG today announced that the two companies have entered into long-term, exclusive commercial license and supply agreements for use of Ligand’s Captisol® technology in the formulation of high-concentration furosemide for the treatment of edema in patients with heart failure. SQ Innovation is developing a novel drug-device combination for cost-effective subcutaneous delivery of diuretics that currently require intravenous administration by a certified healthcare professional. Ligand is eligible to receive poten
Jul 01, 2019 09:00 am ET
ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy. ZULRESSO uses Ligand’s Captisol in its formulation. With this launch, ZULRESSO is the 11th FDA-approved drug to use Ligand’s patented Captisol technology.
Jun 12, 2019 09:00 am ET
Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.
May 17, 2019 09:00 am ET
Ligand Licenses VER250840 to Cumulus Oncology
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP). Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in the mid-to-high single digit range, depending on revenue. In
May 06, 2019 09:00 am ET
Ligand Acquires Milestone and Royalty Rights to SB206 from Novan, Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to SB206 from Novan, Inc. SB206 is a Phase 3 topical antiviral gel for the treatment of skin infections, including molluscum contagiosum. Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20 million in regulatory and commercial milestones. Novan is responsible for all expenses to develop or commercialize SB206, and will use 100% of the proceeds from this transaction i
May 06, 2019 09:00 am ET
Novan Completes Funding Transaction with Ligand Pharmaceuticals
Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has secured $12 million in non-dilutive capital from Ligand Pharmaceuticals Incorporated (“Ligand”) (Nasdaq:LGND). This transaction further enables the...
May 02, 2019 04:01 pm ET
Ligand Reports First Quarter 2019 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2019 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
May 02, 2019 09:00 am ET
Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program is designed to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Ligand also provides below a summary of the findings of a survey of clinicians on radiocontrast agent selection and use.
Apr 18, 2019 09:00 am ET
Ligand to Report First Quarter 2019 Results on May 2nd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2019 financial results on May 2, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Mar 21, 2019 09:00 am ET
Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration’s (FDA) approval of Sage Therapeutics’ (NASDAQ: SAGE) ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO uses Ligand’s Captisol® in its formulation. Ligand is also eligible to receive a royalty on sales of ZULRESSO in the U.S.
Mar 12, 2019 04:01 pm ET
Ligand to Participate in Four Upcoming Investor Conferences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences:
Mar 12, 2019 10:00 am ET
Ligand Provides Highlights from Today’s Analyst Day Event
At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business and financial growth outlook. Management provided additional details on its 2019 financial guidance and a preliminary financial outlook for 2020, discussed its technology platforms, including the opportunity and importance of its OmniAb technology platform.
Mar 11, 2019 10:00 am ET
Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that founder and Chief Executive Officer Dr. David Portman will present...
Mar 05, 2019 04:01 pm ET
Ligand Sells Promacta Assets and Royalty for $827 Million
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand’s Promacta®-related intellectual property rights licensed to Novartis, including the royalty stream on worldwide net sales of Promacta to Royalty Pharma for $827 million in cash. Promacta (eltrombopag) is known as Revolade® outside the U.S. and is marketed worldwide by Novartis. This transaction is expected to close on Wednesday, March 6, 2019.
Mar 05, 2019 07:10 am ET
Detailed Research: Economic Perspectives on Twenty-First Century Fox, Acadia Healthcare, Targa Resources, WellCare Health Plans, Ligand Pharmaceuticals, and Duke Energy — What Drives Growth in Today's
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Twenty-First Century Fox, Inc. (NASDAQ:FOXA), Acadia Healthcare Company,...
Mar 04, 2019 10:00 am ET
Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced it will present a poster on the performance of its lead investigational...
Feb 21, 2019 09:00 am ET
Reminder: Ligand to Host Analyst Day on March 12th in New York City
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.m. to 12:00 p.m. Eastern time (7:00 a.m. to 9:00 a.m. Pacific time) in New York City.
Feb 07, 2019 04:01 pm ET
Ligand Reports Fourth Quarter and Full Year 2018 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions.
Feb 07, 2019 09:00 am ET
Ligand Announces OmniAb® Partnership with Genagon Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with Genagon Therapeutics AB, an immuno-oncology focused biotech located in Sweden. Under the terms of the partnership, Genagon gains access to the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ in their drug discovery efforts. Ligand received an upfront payment and is eligible to receive development milestone payments and tiered royalties for each prod
Feb 04, 2019 04:01 pm ET
Ligand Announces Investment in Dianomi Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces closing an investment in Dianomi Therapeutics, Inc., a biopharmaceutical company focused on improving the delivery and efficacy of large and small molecules in the treatment of a variety of diseases and on therapies for inflammatory diseases, such as osteoarthritis and pain. Ligand paid a total of $3 million to Dianomi in exchange for 1) a tiered royalty of two or three percent based on level of net sales for the first five products to be approved using Dianomi’s patented Minera
Feb 01, 2019 07:40 am ET
Consolidated Research: 2019 Summary Expectations for Micron Technology, Quidel, Ligand Pharmaceuticals, Altra Industrial Motion, USG, and Equity Lifestyle Properties — Fundamental Analysis, Key Perfor
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Micron Technology, Inc. (NASDAQ:MU), Quidel Corporation (NASDAQ:QDEL),...
Jan 29, 2019 12:34 pm ET
Bragar Eagel & Squire, P.C. is Investigating Ligand Pharmaceuticals Incorporated (LGND) on Behalf of Stockholders and Encourages LGND Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND).  Our investigation concerns whether Ligand has violated the federal securities laws and/or engaged in other unlawful business...
Jan 25, 2019 09:00 am ET
Ligand Partner Seelos Therapeutics Becomes a Public Company
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced that it has closed a reverse merger with Apricus Biosciences, Inc. The combined company changed its name to Seelos Therapeutics, Inc., is publicly traded on the Nasdaq Capital Market under the trading symbol “SEEL,” and will focus on the development and commercialization of central nervous system (CNS) therapeutics with known mechanisms of action in areas with high unmet medical need. Seelos is led by Chairman and Chief Executive
Jan 24, 2019 08:01 am ET
Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS)...
Jan 17, 2019 08:00 pm ET
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Ligand Pharmaceuticals Incorporated
The law firm of Kirby McInerney LLP is investigating potential claims against Ligand Pharmaceuticals Incorporated (“Ligand” or the “Company”) (NASDAQ:
Jan 17, 2019 12:45 pm ET
Bragar Eagel & Squire, P.C. is Investigating Ligand Pharmaceuticals Incorporated (LGND) on Behalf of Stockholders and Encourages LGND Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Ligand Pharmaceuticals Incorporated (NASDAQ: LGND).  Our investigation concerns whether Ligand has violated the federal securities laws and/or engaged in other unlawful business...
Jan 17, 2019 10:00 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ligand Pharmaceuticals Incorporated (LGND)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ:  LGND). Such investors are encouraged to obtain...
Jan 16, 2019 05:38 pm ET
Wolf Popper LLP Announces Investigation on Behalf of Investors in Ligand Pharmaceuticals Incorporated
NEW YORK, Jan. 16, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) during the period May 9, 2017 through January 14, 2019, who have incurred losses on their investments in Ligand's securities.  Ligand investors should contact Robert Finkel at 877.370.7703 or at [email protected].
Jan 16, 2019 03:32 pm ET
Rev. Fr. Emmanuel Lemelson Renews Call for Investigation in Alleged Accounting and Securities Fraud, SEC Failures, at Ligand Pharmaceuticals
MARLBOROUGH, Mass., Jan. 16, 2019 /PRNewswire/ -- Rev. Fr. Emmanuel Lemelson, the CIO of Lemelson Capital Management, LLC, a U.S.-based global Investment management firm, today renewed calls for an investigation in Ligand Pharmaceuticals (NASDAQ: LGND), a U.S.-based publicly-traded pharmaceutical company.  
Jan 16, 2019 01:08 pm ET
Former California Deputy Attorney General and Special Prosecutor with Johnson Fistel Launches Investigation into Ligand Pharmaceuticals; Investors Suffering Losses Encouraged to Contact Firm
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP with the assistance of former California Deputy Attorney General and Special Prosecutor, Tiffany Johnson, Esq., is investigating potential claims against Ligand Pharmaceuticals Incorporated ("Ligand") (NASDAQ: LGND).
Jan 15, 2019 02:00 pm ET
Ligand to Report Fourth Quarter and Full Year 2018 Results on February 7th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2018 financial results on February 7, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Dec 18, 2018 05:00 pm ET
Ligand Introduces 2019 Financial Outlook and Raises 2018 Financial Guidance
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) introduces its financial outlook for 2019. Ligand expects revenue in 2019 to be at least $212 million, with up to an additional $40 million of potential milestone and license payments. Approximately two thirds of the $212 million of revenue is expected to be royalty revenue, and the remainder is expected to consist of contract payments and material sales. With projected revenue of $212 million, adjusted earnings per diluted share for 2019 is estimated to be approximately $5.50. So far dur
Dec 17, 2018 04:01 pm ET
Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella Therapeutics
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to PTX-022 from Palvella Therapeutics. PTX-022 is a novel, topical formulation of rapamycin currently in Phase 2/3 development for the treatment of pachyonychia congenita (PC), a rare skin disorder for which no FDA-approved treatment exists. Ligand will pay $10 million to Palvella Therapeutics and in return will receive a tiered royalty on net sales in the mid-to-upper single digits, as well as regulatory and financing milestones. Ligand will n
Dec 17, 2018 09:00 am ET
Vernalis Research, a Ligand Company, Achieves Success Milestone in Collaboration with Asahi Kasei Pharma
Vernalis Research, a Ligand Company, announced the achievement of a £1 million success milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP).
Dec 10, 2018 10:00 am ET
Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s...
Nov 29, 2018 08:50 am ET
Detailed Research: Economic Perspectives on American Tower Corporation (REIT), Ligand Pharmaceuticals, Teva Pharmaceutical Industries, Cummins, Alexander's, and Korea Electric Power — What Drives Grow
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of American Tower Corporation (REIT) (NYSE:AMT), Ligand Pharmaceuticals...
Nov 21, 2018 09:00 am ET
Ligand Announces OmniAb® Partnership with iMetabolic Biopharma Corporation
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company located in Tempe, AZ. Under the terms of the partnership, iMBP gains access to the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ in their drug discovery efforts. Ligand received an up-front license payment and is eligible to receive a tiered royalty on future potential sales
Nov 14, 2018 10:00 am ET
Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the acceptance of three posters for presentation at the 2018 San Antonio...
Nov 13, 2018 09:00 am ET
Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo
Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began in December of 2017.
Nov 08, 2018 08:00 am ET
Ligand Reports Third Quarter 2018 Financial Results
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 9:00 a.m. Eastern time to discuss this announcement and answer questions.
Nov 02, 2018 09:00 am ET
Ligand to Participate in Stephens NY Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in Stephens NY Investment Conference in New York City. Presentation takes place on Wednesday, November 7, 2018, at 1:00 p.m. Eastern time (10:00 a.m. Pacific time). Matt Korenberg, CFO, will attend for Ligand.
Oct 30, 2018 06:09 pm ET
Keysight Technologies Set to Join S&P 500; Ligand Pharmaceuticals to Join S&P MidCap 400; Marcus & Millichap and Arcosa to Join S&P SmallCap 600
NEW YORK, Oct. 30, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600:
Oct 22, 2018 09:15 am ET
Analysis: Positioning to Benefit within Ligand Pharmaceuticals, AptarGroup, Unifirst, Universal, AutoZone, and Churchill Downs — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), AptarGroup, Inc....
Oct 15, 2018 09:00 am ET
Ligand to Report Third Quarter 2018 Results on November 8th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2018 financial results on November 8, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Oct 10, 2018 09:00 am ET
Ligand Announces the Close of its Acquisition of Vernalis
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its acquisition of Vernalis plc has successfully closed and Vernalis will now operate as a subsidiary of Ligand. Vernalis is a structure-based drug discovery biotechnology company with a broad pipeline of partnered programs and ongoing collaborations. In conjunction with this event, Ligand announced that its portfolio now contains more than 178 shots on goal.
Oct 09, 2018 12:00 pm ET
Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced today the appointment of three new members to its Strategic...
Oct 09, 2018 10:00 am ET
Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced the launch of a Phase 2 trial for the treatment of metastatic breast...
Sep 12, 2018 04:13 pm ET
Fr. Emmanuel Lemelson Responds to SEC Charges
MARLBOROUGH, Mass., Sept. 12, 2018 /PRNewswire/ -- Rev. Fr. Emmanuel Lemelson, the Chief Investment Officer of Lemelson Capital Management, today responded to a civil complaint filed by the United States Securities and Exchange Commission in the United States District Court of Massachusetts, Boston Division. In its complaint, the Commission alleges that Fr. Emmanuel engaged in violations of the federal securities laws in connection with transactions in the securities of Ligand Pharmaceuticals Inc. (NASDAQ: LGND), a U.S.-based publicly-traded pharmaceutical company.
Aug 29, 2018 09:00 am ET
Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in H.C. Wainwright 20th Annual Global Investment Conference in New York City. Presentation takes place on Wednesday, September 5, 2018 at 12:30 p.m. Eastern time (9:30 a.m. Pacific time). John Higgins, CEO, and Matt Korenberg, CFO, will attend for Ligand.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.